SCHEMBL24714547

SCHEMBL24714547

CC(C)(C)c1nccc(C(=O)NCCO)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.44
NEK1 Q96PY6 1/20 0.39
S1PR1 P21453 1/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
SYK P43405 1/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
MEN1 O00255 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
HPGD P15428 1/20 0.37
CNR2 P34972 1/20 0.36
MMP13 P45452 1/20 0.36
SCN9A Q15858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24925529 0.83 P2RX7 (0.49) LMNAALDH1A1KDM4ESYKSMN1; SMN2
SCHEMBL24925438 0.81 HDAC1 (0.42) LMNAKDM4ESYKSMN1; SMN2
SCHEMBL20068742 0.80 CNR1 (0.50) CNR1NEK1S1PR1LMNAALDH1A1
SCHEMBL23015806 0.77 CNR1 (0.45) CNR1NEK1S1PR1LMNAALDH1A1
SCHEMBL24714543 0.77 ALDH1A1 (0.35) CNR1LMNAALDH1A1KDM4ESYK
SCHEMBL23015810 0.76 CNR1 (0.44) CNR1NEK1S1PR1LMNAALDH1A1
SCHEMBL2627832 0.75 KDM4E (0.49) LMNAALDH1A1KDM4ESYKKMT2A
SCHEMBL13043849 0.75 ALDH1A1 (0.42) LMNAALDH1A1KDM4ESYKSMN1; SMN2
SCHEMBL31506349 0.75 KDM4E (0.49) LMNAALDH1A1KDM4ESYKKMT2A
SCHEMBL13078469 0.74 SYK (0.35) LMNAALDH1A1KDM4ESYKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 CNR1 2565/4885NEK1 157/4885S1PR1 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.